Haisikar Secures Nearly RMB 100 Million Series A Funding to Accelerate Domestic Production of Pan-Vascular Interventional Devices
VCBeat Exclusively Learns: A Leader in the Field of Pan-vascular InterventionGuangdong Hiscale Medical Technology Co., Ltd.(hereinafter referred to as“Hiscale”）Announced Completion of Nearly RMB 100 MillionSeries A financing, this round of financing was led byQiao Jing CapitalLead investor,Hong Cheng Investment, Rong Tong Capital, Chiron Tianyou, Zhejiang Innovative and Developing CapitalCo-investment.
Hiscale, established in August 2019, is an innovative enterprise dedicated to the research and development of implantable and interventional medical devices for special and complex lesions, as well as the provision of related technologies. As an advanced developer and technology provider of minimally invasive interventional devices, Hiscale possesses a mature platform for the transformation of technological achievements and has masteredPrecision Microfabrication of Medical Materials and Components, Medical Optical Sensing and Ultrafast Lasers, and Precise Control of Medical Energyand other core key technologies. The company has participated in multiple major scientific and technological R&D projects and maintains close collaborations with numerous authoritative medical institutions and research units both domestically and internationally.
After years of development and accumulation, HiscaleEstablished a business layout dominated by comprehensive vascular intervention, with endovascular interventional medical devices as the key development focus., and brings together experts from top international R&D teams in optical, acoustic, and electrical energy control technologies, as well as specialists in the development of medical composite materials and coating processes, along with authoritative clinical and research institutions in China. It builds multi-channel bridges for clinical application, engineering theory, and technology translation to rapidly advance the development and clinical translation of minimally invasive interventional devices, with a pipeline covering minimally invasive access, interventional diagnosis, and precision therapy.
The Company has obtained three Class III medical device registration certificates from the NMPA, covering disposable intravascular guidewires, hydrophilic guidewires, and guiding guidewires. Its product portfolio spans the three major vascular intervention fields: neurovascular, peripheral, and coronary.Hiscale’s independently developed guidewire products demonstrate superior stability and safety in clinical applications. These leading products offer significant advantages in coating smoothness and abrasion resistance of hydrophilic coatings; extreme testing has proven that the coatings maintain their lubricious properties even after more than 130 cycles of repeated friction. Through innovative optimizations in materials, manufacturing processes, and structural design, the products achieve 1:1 torque control while exhibiting excellent trackability and conformability, thereby assisting clinicians in navigating lesions and efficiently establishing surgical access. With quality comparable to top-tier international brands and preferred alternatives in the same category, these products hold substantial application potential.
As of now, Guangdong Hiscale Medical Technology Co., Ltd. has filed 16 patent applications, with 8 patents granted (including one invention patent). The company has 24 products under development, all classified as Class III medical devices, and several of these products have entered the preparatory stage for medical device system review.
Leveraging its unique original innovation capabilities and exceptional product strength, Hiscale entered a fast lane of development in 2023—
On April 20, 2023, Guangdong Hiscale Medical Technology Co., Ltd. signed an agreement with JieChuang MedTech (2190.HK). The two parties will collaborate to launch a co-branded series of guidewire products in the fields of peripheral vascular intervention and neurovascular intervention, and accelerate the commercialization of these products in these two sub-segments of the vascular intervention market, thereby providing innovative vascular access solutions for more patients and healthcare providers in China.
In May 2023, Guangdong Hiscale Medical Technology Co., Ltd. won the second prize in both the Orthopedic Devices Category and the Diagnostic and Treatment Equipment Category of the 6th (2023) China Medical Device Innovation and Entrepreneurship Competition for its “Liquid Crystal-Based Medical Endoscopic Local Gating Imaging Detector.”
Amidst fierce competition, those who strive forge ahead. Guangdong Hiscale Medical Technology Co., Ltd. is tackling the development of interventional devices for more complex and special lesions, actively exploring greater possibilities in disease diagnosis and treatment. Its R&D capabilities cover the full spectrum from underlying technologies to product development, spanning passive to active devices and therapeutic to diagnostic-and-therapeutic solutions, thereby achieving integrated diagnosis and treatment. Committed to becoming one of the few international medical device manufacturers capable of providing one-stop vascular interventional examination equipment and high-value consumables, Hiscale strives to benefit life and health through technological innovation, improve quality of life, and deliver greater clinical benefits.
Yu Zhe, Managing Director of Qiao Jing CapitalGuangdong Hiscale Medical Technology Co., Ltd. has entered the market with medical guidewires, addressing clinical pain points and breaking through bottlenecks in the R&D, design, and manufacturing of domestically produced guidewires. The company focuses on deploying products for neurointerventional, peripheral vascular, and coronary interventional procedures. With a diverse product portfolio that meets current clinical procedural needs, Hiscale is also expanding into active interventional devices, providing high-quality customized products and services to clients and end-user medical institutions. Qiao Jing Capital is committed to identifying and supporting early- to mid-stage medical device projects, leveraging its own resources to assist companies in promoting the industrialization of medical technologies.
Shan Ruiping, Partner at Hongcheng InvestmentIt was stated that, with the intensifying aging of China’s population, the incidence of aortic and peripheral vascular diseases has continued to rise, leading to expanding demand for neurovascular and peripheral interventional medical devices and thereby driving sustained market growth. Hangzhou Hong Cheng Investment Management Co., Ltd. has consistently focused on investment opportunities in this sector. The core team of Guangdong Hiscale Medical Technology Co., Ltd. possesses extensive R&D experience in the interventional field, having established a distinctive and advantageous technology platform and enabling continuous innovation and iteration around its core guidewire products. Hangzhou Hong Cheng Investment Management Co., Ltd. will partner with Guangdong Hiscale Medical Technology Co., Ltd. to accelerate the availability of its products for both domestic and international markets.
Sun Yue, Partner at RongTong CapitalIt was stated that Guangdong Hiscale Medical Technology Co., Ltd. is one of the few emerging enterprises in China’s innovative medical device sector capable of fully independent R&D and manufacturing. The company’s interventional products have demonstrated significant application potential across various clinical indications, with favorable procedural characteristics that meet diverse clinical needs. Its R&D team, combining international perspective with engineering expertise, has successfully overcome multiple key technical challenges in manufacturing processes, enabling large-scale production. The company will continue to deliver its flagship products, including vibration guidewires, hemostasis guidewires, and intravascular multi-parameter functional guidewires. We look forward to the company’s further exploration and global expansion in the field of high-end interventional devices.
Wang Zhiyong, Director of Chiron TianyouStated: "We are deeply honored to have assisted Guangdong Hiscale Medical Technology Co., Ltd. in completing this round of financing. Having witnessed the company’s growth and expansion, we have consistently been bullish on its R&D capabilities, execution efficiency, and commercial strategic layout. We look forward to Hiscale becoming a leader in the interventional field, and we will continue to support its development."
Yu Aiping, President of Zhejiang Innovative and Developing Capital Management Co., Ltd.Statement: It is a great honor to participate in this round of financing for Guangdong Hiscale Medical Technology Co., Ltd. Amidst an unpredictable external environment, the company has consistently adhered to independent innovation, successfully breaking the long-standing technological monopoly held by foreign entities. It has developed domestically produced alternative products through independent R&D and achieved large-scale mass production. We wish the company continued success in demonstrating a renewed international perspective and development strategy, ushering in a new wave of sustained, stable, and high-speed growth.